Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Slides:

Advertisements

Similar presentations

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Advertisements

Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized.

The SPRINT Research Group

Implementing KDOQI CKD Definition and Staging Guidelines in Southern California Kaiser Permanente Mark Rutkowski, MD, Wendy Mann, PharmD, Stephen Derose,

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C

Fredrik Karlsson, MD, Angelo Modica, MD, Thomas Mooe, MD, PhD

Urine Potassium Excretion, Kidney Failure, and Mortality in CKD

Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD: A Longitudinal Study in a Large Japanese.

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD Akshay S. Desai, MD, MPH,

Volume 93, Issue 6, Pages (June 2018)

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G

Uric Acid as a Target of Therapy in CKD

Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and.

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Olivier Niel, MD, PhD, Charlotte Boussard, MSc, Paul Bastard, MSc

Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,

Metabolic Complications in Elderly Adults With CKD

Jessica W. Weiss, MD, Eric S. Johnson, PhD, Amanda Petrik, MS, David H

Francesca Mallamaci, MD, Giovanni Tripepi, PhD

A Decade After the KDOQI CKD Guidelines

The US Renal Data System “Pie Chart of Death”

Comparison of the Performance of 2 GFR Estimating Equations Using Creatinine and Cystatin C to Predict Adverse Outcomes in Elderly Individuals Insa E.

Cardiovascular Disease and CKD: Core Curriculum 2010

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Impact of Electronic Acute Kidney Injury (AKI) Alerts With Automated Nephrologist Consultation on Detection and Severity of AKI: A Quality Improvement.

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

I. Introduction American Journal of Kidney Diseases

Your Kidneys May Outlive You

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study Martin J. Landray, PhD,

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,

Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study Tom Greene, PhD, Chia-Chen Teng, MS, Lesley.

Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis Connie M. Rhee, MD, MSc, Csaba P. Kovesdy,

Association of Waist Circumference and Body Mass Index With All-Cause Mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in.

Guidelines for the Older Adult With CKD

Ioannis Koulouridis, MD, MS, Lori Lyn Price, MAS, Nicolaos E

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, Lisa Hamzah, MRCP, Rachael.

The Kidney Early Evaluation Program (KEEP): Program Design and Demographic Characteristics of the Population Claudine T. Jurkovitz, MD, MPH, Yang Qiu,

Yousef Rezaei, MD American Journal of Kidney Diseases

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

Management of Heart Failure in Advancing CKD: Core Curriculum 2018

Effect of Intensive Insulin Therapy and Pentastarch Resuscitation on Acute Kidney Injury in Severe Sepsis George Thomas, MD, MPH, Ethan M. Balk, MD,

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Socioeconomic Status and Reduced Kidney Function in the Whitehall II Study: Role of Obesity and Metabolic Syndrome Talal M. Al-Qaoud, MD, MSc, Dorothea.

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with.

Use of Diuretics in Heart Failure: A Precarious Balance

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings.

Evidence and Outcomes in CKD

Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial Tadao Akizawa, MD, PhD, Yasushi Asano,

Drug Dose Adjustments in Patients With Renal Impairment

Dennis G. Moledina, MD, Mark A. Perazella, MD

Daniel T. Lackland, DrPH, David J.P. Barker, MD, PhD

Methods for guideline development

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Volume 80, Issue 12, Pages (December 2011)

Off-pump bilateral skeletonized internal thoracic artery grafting in patients with chronic kidney disease Takeshi Kinoshita, MD, PhD, Tohru Asai, MD,

Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Jacob J.E. Koopman, MD, PhD American Journal of Kidney Diseases

Presentation transcript:

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J. Wilson, MD, Rana S. Fayyad, PhD, Andrea Zuckerman, MD, David P. Reed, MD American Journal of Kidney Diseases Volume 53, Issue 5, Pages 741-750 (May 2009) DOI: 10.1053/j.ajkd.2008.11.025 Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Study design and disposition of patients shows chronic kidney disease (CKD) status at baseline. Completed end-point assessments included patients who returned for the final visit, those who died during the study, and those who reported an end point during the study but were either lost to follow-up at the last patient visit or discontinued from the trial before study end. Partial end-point assessments included patients who did not complete the study for various reasons, including discontinuations for adverse events and such administrative issues as withdrawn consent, protocol violations, and loss to follow-up. *Most patients not randomly assigned failed to meet inclusion criteria requiring a history of heart disease. Abbreviation: eGFR, estimated glomerular filtration rate. American Journal of Kidney Diseases 2009 53, 741-750DOI: (10.1053/j.ajkd.2008.11.025) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Mean percentages of change in serum lipid levels from baseline to end of study in patients with eGFR less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Lipid values were available for n = 271 (with CKD, atorvastatin), n = 158 (with CKD, usual care), n = 876 (without CKD, atorvastatin), and n = 568 (without CKD, usual care) patients. ‡P favors usual care. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LS-mean, least-squares mean; TGs, triglycerides; Total-C, total cholesterol. American Journal of Kidney Diseases 2009 53, 741-750DOI: (10.1053/j.ajkd.2008.11.025) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Kaplan-Meier estimates for time to first primary outcome in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD). *Log-rank P. Abbreviations: CI, confidence interval; HR, hazard ratio. American Journal of Kidney Diseases 2009 53, 741-750DOI: (10.1053/j.ajkd.2008.11.025) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Kaplan-Meier estimates for time to first primary outcome in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Log-rank P. Abbreviations: CI, confidence interval; HR, hazard ratio. American Journal of Kidney Diseases 2009 53, 741-750DOI: (10.1053/j.ajkd.2008.11.025) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

Figure 5 Primary and secondary outcome event rates in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Hazard ratio (HR) (95% confidence interval [CI]) and P by means of Cox proportional hazards model with center as a covariate. ‡Unstable angina requiring hospitalization. Abbreviations: CHF, congestive heart failure; MI, myocardial infarction. American Journal of Kidney Diseases 2009 53, 741-750DOI: (10.1053/j.ajkd.2008.11.025) Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions